SR One related stories
All articles and analysis
VC-backed IlluminOss Medical names new VP of financeIlluminOss Medical said Thursday that it has hired Martin Aschenbrener as vice president of finance. Headquartered in East Providence, R.I., IlluminOss is a medical device company focused on developing orthopedic implants. It is backed by Foundation Medical Partners, New Leaf Venture Partners, Tekla Capital, Life Sciences Partners, SR One, Longwood Fund, Excel Venture Management, Pappas Ventures, Mieza Capital and Slater Technology.
- VC group funds formation of F-star Alpha with €9.4 million in Series A funding
F-star, an oncology-focused biopharmaceutical company, has formed F-star Alpha with €9.4 million in Series A funding from Atlas Ventures, Aescap Venture, TVM Capital, SR One, MP Healthcare Venture Management and MS Ventures. F-star Alpha has been granted exclusive license to a range of oncology assets.
- Dicerna Pharma Raises $60 Mln
Dicerna Pharmaceuticals said Thursday it closed $60 million n an oversubscribed Series C round of financing led by new investor RA Capital. Brookside Capital, Deerfield, and Omega Funds also participated. The round also includes all five of Dicerna’s existing institutional investors: Abingworth Management, Domain Associates, Oxford Bioscience Partners, Skyline Ventures and SR One. Watertown, Mass-based Dicerna is a pharmaceutical company developing RNA interference based therapeutics.
- eFFECTOR Therapeutics Raises $45 Million Series A
Biopharmaceutical company eFFECTOR Therapeutics has completed a $45 million Series A financing. Investors include U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage University Partners and Mission Bay Capital.
- KBC and SR One lead €40m Ablynx financing
KBC Private Equity, a Belgian private equity firm, has made its second investment in a Belgian biotechnology firm this week by leading a €40m Series financing for Ablynx, which develops protein products for serious diseases including Alzheimer’s.
- Bicycle Therapeutics Closes $6M Round
Bicycle Therapeutics has closed on 3.75 million ($6 million) in new funding. Current investors Atlas Venture, Novartis Venture Fund, SR One and SV Life Sciences were joined by new investor Astellas Venture Management, the venture capital arm of Astellas Pharma. Bicycle Therapeutics is a biotechnology company based in Cambridge, U.K.
- Nimbus Discovery Names Lynch Executive Chairman
Biotechnology company Nimbus Discovery has appointed Daniel Lynch has been appointed to the company’s board of directors as executive chairman. Lynch will succeed Bruce Booth, D. Phil., partner at Atlas Venture and co-founder of Nimbus, who will remain on the board. Nimbus is backed by life science investors including Atlas Venture, SR One, Lilly Ventures and Gates Ventures.
- Thrasos Therapeutics Inks $35M
Thrasos Therapeutics has raised $35 million for its treatment of acute kidney injury. SR One led the round, with additional funds coming from the GSK Canada Life Sciences Innovation Fund, SW Co., Advanced Technology Ventures, Fonds de solidarité FTQ, Lumira Capital, MP Healthcare Venture Management and Pappas Ventures.
- IlluminOss Medical Closes On $28M
Medical device company IlluminOss Medical Inc. has raised $28 million in Series C financing for its photodynamic orthopedic implants, which are designed to treat fractures through a small entry into the bone. Tekla Capital Management, and Life Sciences Partners co-led the round, with participation of existing investors Foundation Medical Partners, Mieza Capital and New Leaf Venture Partners. New investors in the round included SR One, Excel Venture Management, Pappas Ventures, and the Slater Technology Fund.